Symberix is a preclinical-stage company advancing a new class of microbiome-targeting, small-molecule drugs (SYMBIOTIC DRUGS) that work by selectively eliminating harmful microbial activity in the gut without killing beneficial microbes. A spin-out of University of North Carolina at Chapel Hill, Symberix is developing therapeutic adjuncts to mitigate the debilitating lower gastrointestinal (GI) side effects associated with various cancer, pain and immunosuppressive therapies, as well as monotherapies to treat serious lower GI diseases. Symberix’s internal team has a deep understanding of the biology of the microbiome as well as extensive drug discovery, clinical development and commercial biopharma experience. Symberix’s vision is to deliver safe and effective pharmaceutical control of the microbiome.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):